Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-finding of fixed-dose XM22 vs Neulasta in breast cancer patients receiving chemotherapy
2007-005349-39Phase 2Completed
- Sponsor
- BioGeneriX AG
- Start
- Jan 2008
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial of lipegfilgrastim in chemotherapy-induced neutropenia (CIN) (2 arms), sponsored by BioGeneriX AG. Primary endpoint: Duration of severe neutropenia in cycle 1. Started Jan 2008; status: completed.
02
Drugs
lipegfilgrastim
03
Conditions
chemotherapy-induced neutropenia (CIN)
Beyond the preview
Go deeper on 2007-005349-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-005349-39.